Abstract 556P
Background
Comorbidity has a well documented detrimental effect on cancer survival, but it is difficult to disentangle its direct effect on survival from indirect effects via the influence on treatment choice. This study aimed to assess the impact of comorbidity on survival in colorectal cancer (CRC) patients who underwent similarly aggressive treatment.
Methods
230 CRC patients, 68 rectal (29.6%) and 162 colon cancer (70.4%) treated with surgical resection and neoadjuvant/adjuvant chemotherapy from December 2002 to December 2008 at Humanitas Cancer Center were reviewed. The key independent variable was the Charlson Comorbidity Index (CCI) score. The differences between groups for categorical data were tested by the Chi-square test. Actuarial survival curves were generated using the Kaplan–Meier method.
Results
The median follow-up was of 113 months (range 8.2-145). The median age of patients was 63 (range 37-78). Since all patients had a diagnosis of non-metastatic cancer, the minimum CCI score was 2. In the univariate analysis CCI score, measured as a continuous variable, was significantly associated with poorer progression-free survival (PFS) (HR 1.65, 95%CI 1.52–1.80, p
Conclusions
In this retrospective study we found that a higher CCI score is associated with poorer outcome providing convincing evidence that CCI score is an important negative prognostic factor even after adjusting for other prognostic factors. Some patients with comorbidity may forego chemotherapy unnecessarily, increasing avoidable cancer mortality.
Clinical trial identification
Legal entity responsible for the study
Humanitas Clinical and Research Center
Funding
Humanitas Clinical and Research Center
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract